Insulin-like growth factor I (IGF-I) delays the onset of diabetes in non-obese diabetic (NOD) mice

Y Kaino, H Hirai, T Ito, K Kida - Diabetes research and clinical practice, 1996 - Elsevier
Y Kaino, H Hirai, T Ito, K Kida
Diabetes research and clinical practice, 1996Elsevier
It has been shown that prophylactic exogenous insulin treatment prevents the development
of insulin-dependent diabetes mellitus (IDDM) in animal models and humans. In this study,
we examined whether the development of diabetes and insulitis in female non-obese
diabetic (NOD) mice could be affected by prophylactic administration of insulin-like growth
factor I (IGF-I), which shares structural homology with insulin and has insulin-like metabolic
effects. Two experiments which differed in duration and dosage of IGF-I treatment were …
It has been shown that prophylactic exogenous insulin treatment prevents the development of insulin-dependent diabetes mellitus (IDDM) in animal models and humans. In this study, we examined whether the development of diabetes and insulitis in female non-obese diabetic (NOD) mice could be affected by prophylactic administration of insulin-like growth factor I (IGF-I), which shares structural homology with insulin and has insulin-like metabolic effects. Two experiments which differed in duration and dosage of IGF-I treatment were carried out. In the first experiment, animals were treated from 4 to 9 weeks of age with IGF-I (17.9 nmol/day at 4–5 weeks of age and 35.9 nmol/day at 6–9 weeks of age) and observed up to 34 weeks of age. In the second experiment, the animals were treated from 4 to 34 weeks of age with IGF-I (1.79 nmol/day at 4–5 weeks of age, 3.59 nmol/day at 6–9 weeks of age, and 5.38 nmol/day at 10–34 weeks of age). The former treatment could significantly delay the onset of diabetes (P < 0.05) and decrease the insulitis score at 10 weeks of age (P < 0.01). On the other hand, the latter treatment did not affect the incidence of diabetes, the age at onset or the insulitis score. Our results suggest that the IGF-I treatment at the early age may provide protection against autoimmune β-cell destruction in NOD mice.
Elsevier